Loading
Immunovant, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Dec 2025.
Immunovant, Inc.: what insiders have been doing
Every trade that managers of Immunovant, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 77 filings came from 18 insiders.
Both sides are active: 1 purchase worth €298.1M and 46 sales worth €10.3M, from 1 insider and 10 insiders respectively. The totals do not cover 8 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 senior executive. At €298.1M, the purchase published on 12 December 2025 by Roivant Sciences Ltd. is the largest of the period.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 77 filings here. Looking back to 2021, when coverage begins, insiders filed 9 purchases and 189 sales. For the fiscal year to 31 March 2026, the annual 10-K puts net income at -505.6 m USD.
The most recent open-market purchase was published on 12 December 2025, 310 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
291
Thresholds
n/a
Buy Volume
€630M
9 ops. · all time
Sell Volume
€31M
189 ops. · all time
Who traded when
BuySaleJay S. Stout20 sales
Christopher Van Tuyl9 sales
Melanie Gloria9 sales
Michael Geffner7 sales
Eva Renee Barnett6 sales
Peter Salzmann6 sales
+9 other insiders
Since the insiders bought
- +6.7%Entry US$26.00 · Close 15 Oct 2026 US$27.75
- +292.0%Entry US$9.34 · Close at T+365 US$36.61
- +520.8%Entry US$5.58 · Close at T+365 US$34.64
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Immunovant, Inc. Buy (bullish), based on 16 analysts. Average price target: US$48.88.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
US$27.90
Analyst consensus
16 analystsBuy
US$30.00Target US$48.88(+75%)US$66.00
Income statement
EBITDA-US$532.5M
Net income-US$505.6M0.0% margin
Valuation
PER (forward)-10.1x
P/Book7.8x
Beta0.84
Balance sheet & cash
Market capUS$5.8B
Total debtUS$72k
Free Cash Flow-US$407.3M
Debt / Equity0%
Profitability & ownership
ROE-80.1%
ROA-46.7%
% insiders56.0%
% institutions54.7%
Last declaration on 9 October 2026
Declarations291 total
2,213 shares@ US$32.060.0011% mcap5.0% of flowCommon StockSEC:0001702969-26-000012:0
1,596 shares@ US$32.060.0008% mcap3.6% of flowCommon StockSEC:0001702969-26-000012:1
1,327 shares@ US$32.060.0006% mcap7.0% of flowCommon StockSEC:0001779707-26-000009:0
2,241 shares@ US$32.060.0011% mcap9.4% of flowCommon StockSEC:0001764013-26-000112:0
92,187 shares@ US$14.460.019% mcap9.3% of flowCommon StockSEC:0001764013-26-000110:0
85,886 shares@ US$33.650.041% mcap20.2% of flowCommon StockSEC:0001764013-26-000110:1
3,506 shares@ US$34.110.0017% mcap0.8% of flowCommon StockSEC:0001764013-26-000110:2
2,846 shares@ US$36.360.0015% mcap18.1% of flowCommon StockSEC:0001764013-26-000108:0
1,500 shares@ US$8.430.0002% mcap1.8% of flowCommon StockSEC:0001764013-26-000103:0
1,500 shares@ US$43.270.0009% mcap9.2% of flowCommon StockSEC:0001764013-26-000103:1
3,056 shares@ US$44.160.0019% mcap18.8% of flowCommon StockSEC:0001973838-26-000007:0
6,798 shares@ US$38.690.0037% mcap26.1% of flowCommon StockSEC:0001618670-26-000004:0
1,500 shares@ US$8.430.0002% mcap1.8% of flowCommon StockSEC:0001643071-26-000007:0
1,500 shares@ US$39.800.0008% mcap8.6% of flowCommon StockSEC:0001643071-26-000007:1
2,857 shares@ US$38.690.0016% mcap8.4% of flowCommon StockSEC:0001702969-26-000010:0
106 shares@ US$39.990.0001% mcap0.6% of flowCommon StockSEC:0001764013-26-000083:1
1,906 shares@ US$39.530.0011% mcap5.8% of flowCommon StockSEC:0001764013-26-000081:0
105 shares@ US$39.990.0001% mcap0.3% of flowCommon StockSEC:0001764013-26-000081:1
1,399 shares@ US$39.530.0008% mcap4.2% of flowCommon StockSEC:0001764013-26-000081:2
77 shares@ US$39.990.0000% mcap0.2% of flowCommon StockSEC:0001764013-26-000081:3
1,143 shares@ US$39.530.0006% mcap7.9% of flowCommon StockSEC:0001764013-26-000082:0
63 shares@ US$39.990.0000% mcap0.4% of flowCommon StockSEC:0001764013-26-000082:1
1,930 shares@ US$39.530.0011% mcap10.9% of flowCommon StockSEC:0001764013-26-000083:0
92,188 shares@ US$14.460.019% mcap13.3% of flowCommon StockSEC:0001764013-26-000077:0
86,629 shares@ US$38.140.047% mcap33.1% of flowCommon StockSEC:0001764013-26-000077:1
25 of 291 declarations
About Immunovant, Inc.
Immunovant, Inc. (ticker: IMVT) is a U.S.-based clinical-stage immunology company listed on Nasdaq in the United States. For French-speaking investors, it is best understood as a high-risk, high-upside biotech story rather than a mature pharmaceutical business. The company is focused on autoimmune disease, with a development strategy built around novel monoclonal antibodies that target FcRn, a mechanism designed to reduce pathogenic IgG autoantibodies that drive a range of immune-mediated disorders. Immunovant describes itself as a patient-focused clinical-stage company aiming to enable normal lives for people living with autoimmune diseases.
The company’s roots go back to 2018, when the original operating entity was founded. In December 2019, it completed a transaction with Health Sciences Acquisitions Corporation, after which the combined company adopted the Immunovant, Inc. name and began trading as IMVT on Nasdaq. Immunovant is headquartered in New York, New York, United States, with additional operations in North Carolina. That footprint reflects a classic U.S. biotech structure: corporate leadership and capital markets access in New York, with scientific and operational activity supported elsewhere in the country.
Read moreShow less
Immunovant’s core pipeline is centered on two investigational assets: IMVT-1402 and batoclimab. Both are fully human monoclonal antibodies intended to be administered subcutaneously, with the potential to be tailored by disease stage and severity. The company’s competitive positioning depends on demonstrating deeper and more durable IgG suppression, as well as a clinically meaningful benefit/risk profile versus other FcRn-directed therapies. This is a crowded and strategically important area of immunology, where differentiation will likely come from data quality, dosing flexibility, safety, and the ability to expand across multiple indications.
The main therapeutic areas in development include myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), Graves’ disease, thyroid eye disease (TED), Sjögren’s disease, and cutaneous lupus erythematosus. Immunovant has also highlighted broader potential across autoimmune conditions, reinforcing the platform-like nature of its FcRn strategy.
Recent corporate milestones have been significant. In 2025, Immunovant reported positive Phase 3 results for batoclimab in myasthenia gravis and positive early results in CIDP, supporting the underlying FcRn thesis. Throughout 2025 and into 2026, the company has increasingly positioned IMVT-1402 as its next growth driver while continuing to advance potentially registrational studies in endocrine and autoimmune diseases. In April 2026, the company announced Phase 3 results for batoclimab in thyroid eye disease, an important readout for investors tracking clinical execution and the transition of the pipeline. Overall, Immunovant remains a Nasdaq-listed U.S. clinical biotech with a promising platform, but its valuation and outlook remain heavily dependent on trial outcomes, regulatory progress, and financing capacity.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
